Figure 3From: Exogenous glucagon-like peptide-1 attenuates the glycaemic response to postpyloric nutrient infusion in critically ill patients with type-2 diabetesSerum insulin. When compared to placebo glucagon-like peptide-1 (GLP-1) caused an insulinotropic response (*** at t = 270 minutes: GLP-1: 23.4 ± 6.7 vs. placebo: 16.4 ± 5.5 mU/l; P < 0.05).Back to article page